Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.

Ayyagari, Rajeev; Neary, Maureen; Li, Shang; Rokito, Ariel; Yang, Hongbo; Xie, Jipan; Benson, Al B

Ayyagari, Rajeev; Neary, Maureen; Li, Shang; Rokito, Ariel; Yang, Hongbo; Xie, Jipan; Benson, Al B.

Afiliación

Ayyagari R; Manager, Analysis Group, Boston, MA.
Neary M; Director, Global Value & Access, Novartis Pharmaceuticals, East Hanover, NJ.
Li S; Senior Analyst, Analysis Group, New York, NY.
Rokito A; Senior Analyst, Analysis Group, New York, NY.
Yang H; Vice President, Analysis Group, Boston, MA.
Xie J; Vice President, Analysis Group, New York, NY.
Benson AB; Professor of Medicine, and Associate Director for Cooperative Groups, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.

Am Health Drug Benefits ; 10(8): 408-415, 2017 Nov.

Article en En | MEDLINE | ID: mdl-29263774

Palabras clave

Average Sales Price; CLARINET; GI-NETs; PROMID; Wholesale Acquisition Cost; adverse events; lanreotide; octreotide LAR; sensitivity analyses; treatment cost

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Am Health Drug Benefits Año: 2017 Tipo del documento: Article País de afiliación: Marruecos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google